Deep orbital sub-q restylane (nonanimal stabilized hyaluronic Acid) for orbital volume enhancement in sighted and anophthalmic orbits.

Deep orbital sub-q restylane (nonanimal stabilized hyaluronic Acid) for orbital volume enhancement in sighted and anophthalmic orbits. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Deep orbital sub-q restylane (nonanimal stabilized hyaluronic Acid) for orbital volume enhancement in sighted and anophthalmic orbits. Abstract Text:

Raman Malhotra,Raman Malhotra,Raman Malhotra,

OBJECTIVE: To describe a new technique of injecting Restylane Sub-Q (Q-Med, Uppsala, Sweden) into the intraconal and extraconal posterior orbit. METHODS: Retrospective review. Eight injections were performed in 5 patients using 2-mL Sub-Q in the intraconal and extraconal posterior orbit for orbital volume enhancement. Four injections were performed in sighted orbits and the remaining in anophthalmic orbits. The age range was 18 to 36 years; the follow-up time was 5 to 12 months. RESULTS: Orbital volume enhancement was achieved in all cases with an improvement in upper eyelid sulcus and skin fold. Enophthalmos reduction was 2 mm per 2-mL injection. The procedure was well tolerated. One patient experienced a vasovagal episode lasting 3 hours and 1 patient had postoperative pain. No such episodes occurred after I began injecting local anesthesia before performing the Sub-Q injection. One patient required hyaluronidase for migrating gel, which caused lower eyelid swelling. CONCLUSION: This small case series suggested the safety and tolerability of deep orbital Sub-Q. Injections are easily performed in the outpatient setting. The expected volume enhancement was achieved in all cases with no long-term adverse effects to date.

Deep orbital sub-q restylane (nonanimal stabilized hyaluronic Acid) for orbital volume enhancement in sighted and anophthalmic orbits. Publishing Authors By Initials

R Malhotra,R Malhotra,R Malhotra,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Deep orbital sub-q restylane (nonanimal stabilized hyaluronic Acid) for orbital volume enhancement in sighted and anophthalmic orbits. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Archives of ophthalmology

VOLUME: 125

Page Numbers: 1623-9

Journal Abbreviation: Arch. Ophthalmol.

ISSN: 0003-9950

DAY: 11

MONTH: Dec

YEAR: 2007

Deep orbital sub-q restylane (nonanimal stabilized hyaluronic Acid) for orbital volume enhancement in sighted and anophthalmic orbits. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7706534

Deep orbital sub-q restylane (nonanimal stabilized hyaluronic Acid) for orbital volume enhancement in sighted and anophthalmic orbits. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Deep orbital sub-q restylane (nonanimal stabilized hyaluronic Acid) for orbital volume enhancement in sighted and anophthalmic orbits. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Deep orbital sub-q restylane (nonanimal stabilized hyaluronic Acid) for orbital volume enhancement in sighted and anophthalmic orbits.

AFFILIATION: Corneo-Plastic Unit, Queen Victoria Hospital, Holtye Road, East Grinstead RH19 3DZ, West Sussex, England. malhotraraman@hotmail.com.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Arch Ophthalmol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Deep orbital sub-q restylane nonanimal stabilized hyaluronic Acid for orbital volume enhancement in sighted and anophthalmic orbits Related Publications

• A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia.
• Anaesthetic considerations in a patient with wolff-Parkinson-white syndrome.
• Biosensor for total cholesterol estimation using N-(2-aminoethyl)-3-aminopropyltrimethoxysilane self-assembled monolayer.
• COMT genotype and manic symptoms in schizophrenia.
• COMT genotype increases risk for bipolar I disorder and influences neurocognitive performance.
• Central sleep apnea: Pathophysiology and treatment.
• Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia.
• Corneal astigmatism with upper eyelid gold weight implantation using the combined high pretarsal and levator fixation technique.
• Cytokine release following recruitment maneuvers.
• DTNBP1 genotype influences cognitive decline in schizophrenia.
• Deep orbital sub-q restylane (nonanimal stabilized hyaluronic Acid) for orbital volume enhancement in sighted and anophthalmic orbits.
• Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia.
• Emotion-based decision-making in healthy subjects: short-term effects of reducing dopamine levels.
• Food vacuole targeting and trafficking of falcipain-2, an important cysteine protease of human malaria parasite Plasmodium falciparum.
• Genioglossus premotoneurons and the negative pressure reflex in rats.
• Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics.
• Intense F-18 FDG uptake noted in a benign bone cyst.
• Loop around ear - a simple method for maintaining central venous line with ordinary venous cannula.
• Native manual tonsillectomy: A dangerous practice in Asir.
• Overexpression and purification of human calcitonin gene-related peptide-receptor component protein in Escherichia coli.
• Presumed fresh mutation hemophilia A presenting with subarachnoid hemorrhage in a newborn.
• Renal vein thrombosis: a case report.
• RluD, a highly conserved pseudouridine synthase, modifies 50S subunits more specifically and efficiently than free 23S rRNA.
• Scleral infiltration in orbitotemporal plexiform neurofibromatosis.
• The FEZ1 gene shows no association to schizophrenia in Caucasian or African American populations.
• The Golgi-associated protein GRASP is required for unconventional protein secretion during development.
• The future of pharmacotherapy for schizophrenia.
• The influence of aging on pharyngeal collapsibility during sleep.
• Upper airway myopathy is not important in the pathophysiology of obstructive sleep apnea.
• Use of computational modeling to predict responses to upper airway surgery in obstructive sleep apnea.